Log In
BCIQ
Print this Print this
 

anti-LIGHT mAb (MDGN-002)

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionHuman mAb against tumor necrosis factor (TNF) ligand superfamily member 14 (TNFSF14; LIGHT; CD258)
Molecular Target Tumor necrosis factor (TNF) ligand superfamily member 14 (TNFSF14) (LIGHT) (CD258)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat severe pediatric onset inflammatory bowel disease (IBD); Treat ulcerative colitis (UC)
Regulatory Designation
PartnerAevi Genomic Medicine Inc.;
Sanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/06/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today